Morteza Amestejani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Morteza Amestejani has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Ali Ghaeini Hesarooeih
Breast Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran
1 shared publication- Aliyeh Ranjbar
Breast Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran
1 shared publication Ehsan Kafili
Department of Surgery, Imam Khomeini Hospital, University of Medical Sciences, Urmia, Iran
1 shared publicationHojat Layeg
Department of Surgery, University of Medical Sciences, Ardabil, Iran
1 shared publication- Maral Mokhtari
Department of Pathology, School of Medicine Shiraz University of Medical Sciences Shiraz Iran
1 shared publication - Masoumeh Ghoddusi Johari
Breast Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran
1 shared publication
Latest Publications
- 16 November 2026
- Published by Wiley in Surgical Practice
Comparison of Clinicopathologic Characteristics and Survival Outcome Between Invasive Papillary Carcinoma and Invasive Ductal Carcinoma
Introduction: Invasive papillary carcinoma (IPC) of the breast is an exceptionally rare histological subtype. This study compared the clinicopathological characteristics, biomarker expression profiles and survival outcomes of IPC with those of invasive ductal carcinoma of no special type (IDC‐NST). Materials and Methods: The medical records of 6599 patients treated at the Breast Disease Research Center between December 1993 and December 2021 were retrospectively reviewed. Patients were categorized into IPC ( n = 27) and IDC ( n = 6572) groups. Tumour size, axillary lymph node status, pathologic stage, histologic grade, hormone receptor status (ER, PR), HER2 status, surgical management, adjuvant therapies and survival outcomes were analysed and compared. Survival distributions were evaluated using Kaplan–Meier curves and compared using the log‐rank test. Results: Patients with IPC were significantly older at presentation than those with IDC (mean age: 58.5 ± 14.0 vs. 49.0 ± 12.4 years, p = 0.02). Compared with IDC, IPC tumours demonstrated significantly less aggressive features, including a lower rate of axillary lymph node involvement (14.8% vs. 39.2%, p < 0.001) and a lower incidence of lymphovascular invasion (14.9% vs. 53.3%, p < 0.001). IPC tumours were predominantly low‐grade (Grade I: 70.3% vs. 20.5%, p < 0.001) and presented more frequently at Stage I (85.1% vs. 39.8%, p < 0.001). Adjuvant chemotherapy was administered significantly less often in the IPC group than in the IDC group (62.9% vs. 94.9%, p < 0.001). In stage‐specific analyses of Stage I disease, IPC exhibited favourable 5‐year disease‐free survival (81% vs. 69%, p = 0.008) and 5‐year overall survival (85% vs. 75%, p = 0.001) compared with Stage I IDC. Conclusion: IPC is a rare tumour type that presents unique clinicopathological characteristics and is associated with a higher rate of breast‐conserving surgery and a favourable prognosis than IDC.
- 16 November 2026
- Published by Wiley in Surgical Practice
Comparison of Clinicopathologic Characteristics and Survival Outcome Between Invasive Papillary Carcinoma and Invasive Ductal Carcinoma
Introduction: Invasive papillary carcinoma (IPC) of the breast is an exceptionally rare histological subtype. This study compared the clinicopathological characteristics, biomarker expression profiles and survival outcomes of IPC with those of invasive ductal carcinoma of no special type (IDC‐NST). Materials and Methods: The medical records of 6599 patients treated at the Breast Disease Research Center between December 1993 and December 2021 were retrospectively reviewed. Patients were categorized into IPC ( n = 27) and IDC ( n = 6572) groups. Tumour size, axillary lymph node status, pathologic stage, histologic grade, hormone receptor status (ER, PR), HER2 status, surgical management, adjuvant therapies and survival outcomes were analysed and compared. Survival distributions were evaluated using Kaplan–Meier curves and compared using the log‐rank test. Results: Patients with IPC were significantly older at presentation than those with IDC (mean age: 58.5 ± 14.0 vs. 49.0 ± 12.4 years, p = 0.02). Compared with IDC, IPC tumours demonstrated significantly less aggressive features, including a lower rate of axillary lymph node involvement (14.8% vs. 39.2%, p < 0.001) and a lower incidence of lymphovascular invasion (14.9% vs. 53.3%, p < 0.001). IPC tumours were predominantly low‐grade (Grade I: 70.3% vs. 20.5%, p < 0.001) and presented more frequently at Stage I (85.1% vs. 39.8%, p < 0.001). Adjuvant chemotherapy was administered significantly less often in the IPC group than in the IDC group (62.9% vs. 94.9%, p < 0.001). In stage‐specific analyses of Stage I disease, IPC exhibited favourable 5‐year disease‐free survival (81% vs. 69%, p = 0.008) and 5‐year overall survival (85% vs. 75%, p = 0.001) compared with Stage I IDC. Conclusion: IPC is a rare tumour type that presents unique clinicopathological characteristics and is associated with a higher rate of breast‐conserving surgery and a favourable prognosis than IDC.
- Open Access
- 30 December 2021
- Published by SAGE Publications in Surgical Innovation
- Vol. 29 (6) , 742-746
The Association of Vitamin D3 With Early Anastomotic Leakage in Patients Undergoing Hemicolectomy Surgery
Anastomotic leak (AL) is one of the most important postoperative complications after hemicolectomy with stapled anastomosis. This study aimed to evaluate the association of preoperative vitamin D3 with early anastomotic leakage after right colon cancer surgery with stapled anastomosis. In this prospective cohort study, 535 patients who underwent right colon cancer surgery (right hemicolectomy) with stapled anastomosis were enrolled. A subset of 315 patients was included in the study after meeting the inclusion criteria. Preoperative vitamin D level was measured and analyzed for association with early AL using univariable and multivariable logistic regression analyses. This study included 315 cases; among them, 18 (5.71%) patients developed early AL. Vitamin D3 was significantly higher among patients without early AL (P < .001). Low vitamin D3 status was reported among 111 patients (35.2%) and 204 (64.8%) of patients did not have low vitamin D3 status (sufficient level = 30-100 ng/mL). Sufficient vitamin D3 levels before right colon cancer surgery with stapled anastomosis was associated inversely with early AL (crude OR = .89, 95% CI = .85-.94, P < .001 and adjusted OR = .89, 95% CI = .82-.98, P = .02). The vitamin D3 level has a protective association with early AL. As a result, low vitamin D3 status may be a risk factor for early AL development, suggesting that it can be one of the predictors of early AL occurrence.
- 30 December 2021
- Published by SAGE Publications in Surgical Innovation
- Vol. 29 (6) , 742-746
Open AccessThe Association of Vitamin D3 With Early Anastomotic Leakage in Patients Undergoing Hemicolectomy Surgery
Anastomotic leak (AL) is one of the most important postoperative complications after hemicolectomy with stapled anastomosis. This study aimed to evaluate the association of preoperative vitamin D3 with early anastomotic leakage after right colon cancer surgery with stapled anastomosis. In this prospective cohort study, 535 patients who underwent right colon cancer surgery (right hemicolectomy) with stapled anastomosis were enrolled. A subset of 315 patients was included in the study after meeting the inclusion criteria. Preoperative vitamin D level was measured and analyzed for association with early AL using univariable and multivariable logistic regression analyses. This study included 315 cases; among them, 18 (5.71%) patients developed early AL. Vitamin D3 was significantly higher among patients without early AL (P < .001). Low vitamin D3 status was reported among 111 patients (35.2%) and 204 (64.8%) of patients did not have low vitamin D3 status (sufficient level = 30-100 ng/mL). Sufficient vitamin D3 levels before right colon cancer surgery with stapled anastomosis was associated inversely with early AL (crude OR = .89, 95% CI = .85-.94, P < .001 and adjusted OR = .89, 95% CI = .82-.98, P = .02). The vitamin D3 level has a protective association with early AL. As a result, low vitamin D3 status may be a risk factor for early AL development, suggesting that it can be one of the predictors of early AL occurrence.